Nursing facility
Hayward Sisters Hospital
Hayward Sisters Hospital was paid $15.14M by Medicaid between Jan 2018 and Dec 2024, across 176 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoHAYWARD SISTERS HOSPITAL
HAYWARD, CA 94545
HAYWARD, CA 94545
33aNPI1942298153assigned 10/11/2005
33bProvider typeSkilled Nursing Facility
28Total paid$15.14M
24GClaims502,277
24DCodes billed176
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Skilled Nursing Facility providers in California
Rank by total paid#9 of 547
Median peer was paid$73K
This provider vs. median207×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 95,908 | $2.49M | |
| 2019 | 80,855 | $2.07M | |
| 2020 | 50,752 | $1.54M | |
| 2021 | 60,142 | $2.07M | |
| 2022 | 77,799 | $2.56M | |
| 2023 | 84,080 | $2.50M | |
| 2024incomplete | 52,741 | $1.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 56,542 | 50,901 | $2.04M |
| 0450 | Emergency room services | 8.7% | 9,267 | 8,479 | $1.31M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.6% | 11,538 | 10,718 | $1.14M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.1% | 2,169 | 2,114 | $775K |
| 80053 | Comprehensive metabolic panel | 4.0% | 30,608 | 27,825 | $613K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.0% | 19,828 | 18,299 | $610K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 3,399 | 3,316 | $561K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.7% | 6,560 | 6,409 | $555K |
| 99070 | 3.2% | 29,273 | 13,874 | $489K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.0% | 6,964 | 6,424 | $460K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 36,570 | 33,062 | $391K |
| 99199 | Unlisted special service, procedure or report | 2.5% | 6,176 | 5,475 | $384K |
164 more codes
| Z7502 | 2.3% | 9,521 | $355K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 6,618 | $300K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 1,339 | $281K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.6% | 3,535 | $240K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 1,643 | $208K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 10,090 | $199K |
| 59050 | 1.2% | 1,381 | $177K | |
| 83880 | 1.1% | 4,168 | $174K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,546 | $167K |
| J3490 | Unclassified drugs | 1.0% | 23,117 | $158K |
| 84484 | 1.0% | 10,863 | $156K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 3,520 | $152K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,091 | $142K |
| 80306 | <1% | 4,249 | $120K | |
| 99221 | <1% | 389 | $110K | |
| 81001 | <1% | 19,024 | $105K | |
| 83690 | <1% | 9,379 | $104K | |
| 87275 | <1% | 8,239 | $102K | |
| 87276 | <1% | 8,239 | $95K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,084 | $93K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,409 | $72K |
| 80299 | <1% | 3,046 | $65K | |
| 87280 | <1% | 3,740 | $63K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,451 | $62K |
| 99218 | <1% | 369 | $62K | |
| 76801 | <1% | 637 | $60K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,019 | $59K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 149 | $58K |
| 81025 | <1% | 9,699 | $55K | |
| 87430 | <1% | 3,331 | $53K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 3,255 | $51K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 918 | $51K |
| 87088 | <1% | 4,807 | $51K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 195 | $50K |
| 99283 | Emergency room visit (moderate) | <1% | 854 | $49K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,800 | $49K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 519 | $48K |
| 87070 | <1% | 3,214 | $46K | |
| Z7610 | <1% | 5,221 | $44K | |
| 83605 | <1% | 2,667 | $43K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 344 | $42K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,574 | $39K |
| 71250 | <1% | 221 | $37K | |
| 59025 | Fetal non-stress test | <1% | 1,291 | $37K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,202 | $37K |
| 83735 | <1% | 3,909 | $37K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,400 | $36K |
| 87040 | <1% | 1,800 | $35K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,379 | $34K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 1,285 | $34K |
| 76830 | Ultrasound, transvaginal | <1% | 387 | $32K |
| 73560 | <1% | 1,238 | $32K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,021 | $31K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 406 | $31K |
| 84702 | <1% | 1,323 | $29K | |
| 73610 | <1% | 722 | $25K | |
| 73630 | <1% | 765 | $25K | |
| 81003 | <1% | 4,599 | $24K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 99 | $24K |
| Z9725 | <1% | 519 | $22K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,083 | $22K |
| 87186 | <1% | 1,827 | $22K | |
| 85379 | <1% | 1,380 | $21K | |
| 0250 | <1% | 6,208 | $21K | |
| 94060 | <1% | 309 | $20K | |
| 73564 | <1% | 431 | $20K | |
| 87797 | <1% | 695 | $20K | |
| 85610 | <1% | 3,452 | $19K | |
| 94644 | <1% | 598 | $19K | |
| 88342 | <1% | 176 | $19K | |
| 86141 | <1% | 1,019 | $18K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 332 | $18K |
| 73030 | <1% | 440 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 935 | $14K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,823 | $14K |
| 87081 | <1% | 1,223 | $13K | |
| 94726 | <1% | 279 | $13K | |
| 90715 | <1% | 241 | $13K | |
| 94729 | <1% | 283 | $13K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 278 | $13K |
| 73562 | <1% | 398 | $12K | |
| 85730 | <1% | 1,226 | $11K | |
| 86900 | <1% | 1,193 | $11K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,841 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 101 | $10K |
| 82962 | <1% | 1,976 | $9K | |
| 86901 | <1% | 1,608 | $9K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 97 | $9K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,747 | $9K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 59 | $9K |
| 93971 | <1% | 58 | $7K | |
| 73565 | <1% | 338 | $7K | |
| 82010 | <1% | 596 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 145 | $7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,206 | $6K |
| 87807 | <1% | 376 | $6K | |
| 87806 | <1% | 104 | $6K | |
| 73130 | <1% | 154 | $6K | |
| 96367 | <1% | 80 | $6K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,021 | $5K |
| 72100 | <1% | 145 | $5K | |
| 84439 | <1% | 371 | $5K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 55 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 734 | $5K |
| 87210 | <1% | 675 | $5K | |
| 86850 | <1% | 626 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 499 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 522 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 235 | $4K |
| 73502 | <1% | 73 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 17 | $4K |
| 82803 | <1% | 127 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 220 | $3K |
| 85651 | <1% | 677 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 446 | $3K |
| 84703 | <1% | 252 | $3K | |
| 86480 | <1% | 58 | $3K | |
| 74018 | <1% | 86 | $3K | |
| 87449 | <1% | 226 | $3K | |
| 95816 | <1% | 40 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $2K |
| 82550 | <1% | 269 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 413 | $2K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 770 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 404 | $2K |
| 73020 | <1% | 84 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 311 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 237 | $2K |
| 45384 | <1% | 47 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 12 | $2K |
| 95819 | <1% | 29 | $2K | |
| 84145 | <1% | 59 | $2K | |
| 86592 | <1% | 173 | $2K | |
| 73110 | <1% | 40 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 189 | $2K |
| 0270 | <1% | 182 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 397 | $1K |
| 86762 | <1% | 44 | $1K | |
| 94617 | <1% | 14 | $1K | |
| 73120 | <1% | 42 | $1K | |
| 74740 | <1% | 12 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 180 | $978.55 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 212 | $914.55 |
| 80320 | <1% | 455 | $845.99 | |
| 88304 | <1% | 13 | $838.20 | |
| 87147 | <1% | 82 | $617.63 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 161 | $593.33 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 15 | $589.54 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 96 | $522.39 |
| 80061 | Lipid panel | <1% | 25 | $485.17 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 136 | $460.48 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $424.89 |
| 86308 | <1% | 52 | $406.24 | |
| 87205 | <1% | 56 | $315.77 | |
| A9270 | Non-covered item or service | <1% | 1,576 | $313.25 |
| 72170 | <1% | 14 | $285.42 | |
| 84550 | <1% | 26 | $195.55 | |
| 82950 | <1% | 18 | $178.16 | |
| 0637 | <1% | 1,064 | $151.24 | |
| J2704 | Injection, propofol, 10 mg | <1% | 46 | $134.91 |
| 85008 | <1% | 104 | $109.77 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 26 | $109.55 |
| A4554 | Disposable underpads, all sizes | <1% | 16 | $59.04 |
| 0271 | <1% | 16 | $17.96 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREDDY, LEX (PRESIDENT AND CEO)